$PLSM

Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring

Pulsenmore Ltd. (Nasdaq: PLSM) (TASE: PLSM) has completed CE European registration for its home ultrasound system, Pulsenmore FC, expanding into fertility care. The system allows patients to perform scans at home, reducing clinic visits. Over 1.15 million assisted reproduction treatment cycles were reported in Europe in 2023, with many requiring repeated ultrasounds. The company aims to market the system across Europe, following approval in Israel and a commercial agreement with Clalit Health Se

Original reporting
Published Sep 8, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring — source image
Decision brief

The 30-second read

$PLSMBullishMed
01

Why it matters

The EU MDR registration is a material corporate milestone, opening a new revenue stream and potentially boosting the stock.

02

Market read

First‑time EU clearance for a fertility‑care ultrasound device; could drive stock re‑rating.

03

What to watch

Reimbursement policies and competition from established imaging companies may constrain growth.

Relevance 6/10Novelty 6/10Timing: Sep 8 2026 (registration announced)

Background

Pulsenmore, a Nasdaq‑listed med‑tech company, previously focused on prenatal monitoring and now expands into fertility care with a CE‑marked home ultrasound system.

Company-level read

Ticker impact

$PLSMBullishMedium confidence
Context

Pulsenmore completed European MDR registration for its home ultrasound fertility care system, enabling sales across Europe.

Expected impact

Potential upside as investors price in European market expansion.

Evidence & confidence

First disclosure of EU registration; no prior public announcement, but scale is limited to a niche medical device.

Market effects

May spur interest in home‑ultrasound and digital health firms targeting women's health.

European fertility clinics could adopt the technology, increasing demand for related services.

Highlights trend toward remote diagnostics, relevant to med‑tech investors worldwide.

Counterpoint

Adoption could be slower due to regulatory nuances and clinician acceptance, limiting near‑term upside.

Key entities

  • Pulsenmore Ltd.

    Developer of self‑use ultrasound devices, listed on Nasdaq (PLSM).

  • Clalit Health Services

    Israeli health insurer partnering with Pulsenmore for commercial rollout.

Related articles

$PLSMMed

Pulsenmore Ltd.: Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) has registered its home ultrasound system, Pulsenmore FC, with the UK's MHRA, allowing it to market the product in the UK and Northern Ireland. The system is designed for women undergoing IVF and fertility preservation treatments, enabling at-home monitoring. The UK fertility market saw over 100,000 treatment cycles in 2024, according to the HFEA. This expansion follows the company's recent European registration under the Medical Device Regulation (MDR

$PLSMMed

Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore (NASDAQ: PLSM, TASE: PLSM) has expanded its fertility platform into the UK after completing MHRA registration for its home ultrasound system, Pulsenmore FC. The system allows women undergoing IVF to perform vaginal ultrasound scans at home, reducing clinic visits. The UK market saw over 100,000 fertility treatment cycles in 2024, according to the HFEA.

$PLSMMed

Pulsenmore Ltd. (PLSM): Financial results for H1 2026

Pulsenmore Ltd. (PLSM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update Omer, Israel –August 31, 2026 – Pulsenmore Ltd. (Nasdaq/TASE: PLSM ), a leadin

$PLSMMed

Pulsenmore stock surges 160% on Israel AI program selection By Investing.com

Pulsenmore Ltd. (NASDAQ:PLSM) shares jumped about 160% after the company said it was selected for Israel’s Healthcare AI Regulatory Sandbox Program by the Israel Innovation Authority and Ministry of Health. Pulsenmore will receive funding for a $1 million project to develop and clinically validate AI for its home ultrasound platform, with Beilinson Hospital/Clalit Health Services.

$ACNLow

Anthropic and Accenture to partner in frontier AI models evaluation as safety concerns rise – Ya Libnan

Anthropic and Accenture (ACN) announced a partnership to independently evaluate Anthropic's AI models, with each committing at least $1 billion over five years. The move comes amid rising safety concerns and regulatory pressure on AI developers. Accenture's Faculty unit will lead the evaluation, conducting assessments and testing safeguards. The partnership aims to address risks and benefits of advanced AI models, with a focus on safety and transparency.

$005930.KSMedAI 9/10

Samsung’s Unusual AI Bet: It Invests in Euclid in Search of a Future Beyond HBM

Samsung Electronics invested $214M in Dutch AI chip startup Euclid, focusing on processor-memory co-design for AI inference. Euclid's Craftwork system aims to improve efficiency by integrating compute and memory, reducing data-transfer time and power consumption. Samsung seeks to expand beyond HBM production into AI compute and memory architectures, targeting the growing inference market.